Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.57 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.47 |
| ▸ | MTTP | P55157 | 7/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4859664 | 0.81 | MAPK14 (0.79) | MAPK14MAPK11 | |
| SCHEMBL4864387 | 0.77 | MAPK14 (0.74) | MAPK14MAPK11KDM4EALDH1A1HPGD | |
| SCHEMBL6603680 | 0.77 | MCL1 (0.55) | MAPK14MAPK11GAAALDH1A1HPGD | |
| SCHEMBL4864471 | 0.74 | MAPK14 (0.76) | MAPK14MAPK11 | |
| SCHEMBL4863522 | 0.73 | MAPK14 (1.00) | MAPK14MAPK11 | |
| SCHEMBL7617123 | 0.72 | MTTP (0.55) | MTTPPPARGKDM4EALDH1A1HPGD | |
| SCHEMBL4855124 | 0.71 | MAPK14 (0.85) | MAPK14MAPK11 | |
| SCHEMBL6605924 | 0.70 | MAPK14 (0.83) | MAPK14MAPK11 | |
| SCHEMBL4858295 | 0.70 | MAPK14 (0.83) | MAPK14MAPK11 | |
| SCHEMBL4856613 | 0.70 | MAPK14 (0.83) | MAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384963-B2 | 2′-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase | GLAXO GROUP LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| US-20040266839-A1 | 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266839-A1 | 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors | MAPK1, MAPK3, MAPK6 | MAPK14 11/4885BACE1 2760/4885MAPK11 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.